Chemoimmunotherapy improves survival in solid tumors regardless of liver metastasis status
Chemoimmunotherapy helps solid tumor patients, with or without liver metastases
This systematic review and meta-analysis evaluated 25915 patients with solid tumors receiving chemoimmunotherapy versus chemotherapy alone. …
For people with solid tumors, adding immunotherapy to chemo helps survival whether or not cancer has spread to the liver.
Immune checkpoint inhibitors before lung cancer surgery show acceptable safety profile
Immunotherapy before lung cancer surgery is safe, study finds
This meta-analysis of patients with resectable non-small cell lung cancer found that neoadjuvant or perioperative immune checkpoint inhibito…
A new analysis of 2,691 patients shows that immunotherapy before lung cancer surgery is feasible, but comes with specific surgical challenge…
Cutaneous immune-related adverse events associated with improved progression-free survival in non-small cell lung cancer
Skin reactions in lung cancer patients may signal longer life with certain treatments
This meta-analysis evaluated patients with non-small cell lung cancer receiving anti-PD-1, PD-L1, or chemotherapy. The analysis found that c…
A large review found that specific skin reactions linked to cancer drugs are connected to longer survival times for some lung cancer patient…
Case report review highlights suspicion of breast cancer metastasis to thyroid in a 54-year-old woman
Breast cancer can spread to the thyroid gland in rare cases
This case report review describes a 54-year-old woman with a history of breast cancer who developed metastasis to the thyroid. The authors n…
A single case report shows a 54-year-old woman survived after breast cancer spread to her thyroid, highlighting the need for careful diagnos…
Network meta-analysis suggests immune checkpoint inhibitor regimens improve survival in advanced gastric cancer compared to chemotherapy alone
New analysis suggests dual-target immune checkpoint inhibitors may improve survival for advanced gastric cancer patients
This network meta-analysis evaluated immune checkpoint inhibitor regimens versus chemotherapy for patients with advanced gastric cancer. The…
A large network meta-analysis suggests dual-target immune checkpoint inhibitors combined with chemotherapy may improve survival for advanced…
PD-1/PD-L1 inhibitors improve response in dMMR/MSI-H metastatic colorectal cancer
New meta-analysis shows PD-1 inhibitors improve response rates for dMMR colorectal cancer
This meta-analysis of 1460 patients with dMMR/MSI-H metastatic colorectal cancer found that PD-1/PD-L1 monotherapy significantly improved ob…
A large review of 1460 patients found PD-1 inhibitors significantly improved tumor response rates compared to chemotherapy for dMMR colorect…
Meta-analysis links emotional distress to worse outcomes in advanced lung cancer
Emotional distress linked to worse lung cancer survival
This systematic review and meta-analysis of 911 patients with advanced NSCLC found emotional distress was significantly associated with redu…
For people with advanced lung cancer, feeling emotionally distressed is tied to lower survival and worse treatment response, a new analysis …
Network meta-analysis compares therapies for liver metastatic uveal melanoma
Liver-directed therapy combined with ICIs leads for metastatic uveal melanoma survival
This systematic review and network meta-analysis synthesized evidence on therapeutic modalities for patients with liver metastatic uveal mel…
A network meta-analysis of 2,585 patients found liver-directed therapy combined with immune checkpoint inhibitors offered the best survival …
Morning immune checkpoint inhibitor infusions associated with improved survival in metastatic non-small-cell lung cancer
Giving cancer immunotherapy in the morning may help patients live longer
This emulated pragmatic randomized controlled trial in Veterans Health Administration patients with stage IV non-small-cell lung cancer foun…
Giving immunotherapy in the morning instead of the afternoon appears to help advanced lung cancer patients live longer, a large study found.
Meta-analysis of neoadjuvant anti-PD-1/PD-L1 plus chemotherapy in resectable NSCLC reports resection and response rates
Combining checkpoint inhibitors with chemotherapy helps more lung cancer patients get surgery safely
This meta-analysis synthesized outcomes from 1,885 patients with potentially resectable non-small cell lung cancer who received neoadjuvant …
A review of 1,885 patients found that adding immune therapy to standard chemo before surgery helped many get clean operations. About one in …
Neoadjuvant ICI plus chemotherapy improves event-free survival in early-stage TNBC
Adding immune drugs to chemo helps early stage triple negative breast cancer patients stay disease free longer
A meta-analysis found neoadjuvant immune checkpoint inhibitors with chemotherapy significantly improved event-free survival but not overall …
A large review of trials found that adding immune checkpoint inhibitors to chemotherapy improves survival chances for early stage triple neg…
High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors
High Mutation Counts May Predict Better Cancer Survival Outcomes
This systematic review and meta-analysis evaluated 5278 patients with solid tumours treated with immune checkpoint inhibitors or chemotherap…
High mutation counts in tumors may help predict who will survive longer when taking powerful immune-boosting cancer drugs